Read on Twitter
More DD on $TCNNF, more it makes sense to be second highest weighting in portfolio. @rivers_kim
Increase guide of $465-485M rev 2020 still too low with almost 50% adj EBITDA. Edibles working through lab testing now and will start flowing non-stop Q4.
$MSOS $CURLF $CRLBF
1/
Increase guide of $465-485M rev 2020 still too low with almost 50% adj EBITDA. Edibles working through lab testing now and will start flowing non-stop Q4.
$MSOS $CURLF $CRLBF
1/
FL patient count exploding to over 20k new per month and Trulieve gaining new patient $. Their Dr. referral and call center build brand loyalty immediately for new patients. 400k total patients in FL and estimate a 5% penetration of 21M pop. 800k-1M potential under current law.
With this FL growth and considering the expansion into MA CA and maybe GA, I expect 2021 rev $800-1bln. Current market cap suggests slightly over 2x 2021 rev and 5x 2021 EBITDA. Another potential 3-5x re-rate soon. Embarrassing volume on OTC markets for such a beast. 150M in cash
Now second holding and significant weight. Any price in the low 20's is a steal. Timestamp and we will revisit in December. FL dealing with budget issues and will most likely pull forward adult-use in 2021 -- if this happens we need much BIGGER assumptions. 
